Background Cancer patients receiving chemotherapy have an increased risk of
cardiovascular complications. This limits the widespread use of lifesaving therapies, often …

Purpose of review As cancer survivor rates improve with early screening and modern
treatment options, cardiotoxicity is becoming an increasing problem. It is imperative for …

Drug-induced cardiotoxicity is a life-threatening side effect of doxorubicin (DOX) treatment
that impacts patient prognosis and survival. In the majority of cases, the acute clinical form …

Background Several measures including drugs have been tried to reduce anthracycline
cardiotoxicity. The lack of randomized trials prompted this study to assess the role of an …

Doxorubicin (DOX) is a widely used chemotherapy drug that can cause significant
cardiotoxicity, limiting its clinical application. This study aimed to investigate the potential …

The aim of this study was to investigate the usefulness of three-dimensional (3D) speckle
tracking echocardiography (STE) for assessment of both left and right ventricular systolic …

Anthracycline chemotherapy serves an important role in treating patients with breast cancer
but is associated with cardiotoxicity. Although brain natriuretic peptide (BNP) is not the ideal …

Background/Purpose This study aims to quantify the utility of monitoring LVEF, hs-cTnT, and
NT-proBNP for dynamic cardiotoxicity risk assessment in women with HER2+ early breast …

Background The clinical application of anthracycline chemotherapy is hindered due to the
cumulative dose-dependent cardiotoxicity followed by the oxidative stress initiated during …

The explosive growth of novel cancer therapies in the last decade has led to dramatic
improvements in the survival of patients with cancer. 1 The occurrence of poorly understood …